Evidence map›Paper›PMID 38603567›Full record

ArticleBlood advances2024

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival.

Shai Shimony, Julia Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. BPDCN: state of the art.Hematology. American Society of Hematology. Education Program · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Shai ShimonyDivision of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7245-9652
Julia KeatingDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Christopher J FayDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA.ORCID 0000-0002-3278-1417
Marlise R LuskinDivision of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-5781-4529
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Nicole R LeBoeufDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA.ORCID 0000-0002-8264-834X
Andrew A LaneDivision of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7380-0226
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USTel Aviv University · IL

Funding

Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)R37CA225191 · NCI · DANA-FARBER CANCER INST · PI LANE, ANDREW A · 2018 to 2024
$3.0M
NCI NIH HHS R37 CA225191
6 · The paper itself

Abstract

abstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) can involve skin, bone marrow (BM), central nervous system (CNS), and non-CNS extramedullary sites. Preclinical models demonstrated clonal advantage of TET2-mutated plasmacytoid dendritic cells exposed to UV radiation. However, whether sun exposure, disease characteristics, and patient survival are clinically related is unclear. We classified organ involvement in 66 patients at diagnosis as skin only (n = 19), systemic plus skin (n = 33), or systemic only (n = 14). BM involvement was absent, microscopic (<5%), or overt (≥5%). UV exposure was based on clinical and demographic data. Patients with skin only BPDCN were more frequently aged ≥75 years (47% vs 19%; P = .032) and had lower rates of complex karyotype (0 vs 32%, P = .022) and mutated NRAS (0 vs 29%, P = .044). Conversely, those without skin involvement had lower UV exposure (23% vs 59%, P = .03) and fewer TET2 mutations (33% vs 72%, P = .051). The median overall survival (OS) was 23.5, 20.4, and 17.5 months for skin only, systemic plus skin, and systemic only, respectively. Patients with no BM involvement had better OS vs overt involvement (median OS, 27.3 vs 15.0 months; P = .033) and comparable with microscopic involvement (27.3 vs 23.5 months; P = .6). Overt BM involvement remained significant for OS when adjusted for baseline characteristics and treatment received. In summary, BPDCN clinical characteristics are associated with disease genetics and survival, which together may impact prognosis and indicate informative disease subtypes for future research.

Indexed as

DioxygenasesDNA-Binding ProteinsMutationProto-Oncogene ProteinsAdultAgedAged, 80 and overDendritic CellsFemaleGTP PhosphohydrolasesHematologic NeoplasmsHumansMaleMembrane ProteinsMiddle AgedNeoplasmsDioxygenasesDNA-Binding ProteinsGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteinsras ProteinsTET2 protein, human

Identifiers

PMID38603567
PMCPMC11176947
OpenAlexW4394711385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.